Crinetics Pharmaceuticals, Inc.
CRNX NASDAQHealthcare ★★★★★Latest Earnings
Date
Aug 3, 2026
ET
EPS Est.
-1.18
EPS Actual
-1.14
Revenue Est.
$14.8M
Revenue Actual
$25.1M
Next Earnings Report
Date
Nov 5, 2026 · Thu
Time
After-market
Fiscal Period
FY2026 Q3
EPS Est.
-1.20
Revenue Est.
$21M
Company Overview
Crinetics Pharmaceuticals, Inc. (ticker CRNX) is listed on NASDAQ with a market cap of about $8.97B. Its next earnings report (FY2026 Q3) is expected on Nov 5, 2026 (ET), After-market, with consensus EPS of -1.20. In the last 15 reported quarters, EPS beat consensus estimates 3 times.
Actual EPS TrendRecently15Term · Feb 28, 2023 → Aug 3, 2026
Feb 28, 2023Range: -1.38 ~ -0.84Aug 3, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 3, 2026 | -- | -1.18 | -1.14 | $14.8M | $25.1M |
| May 7, 2026 | -- | -1.22 | -1.23 | $8.5M | $10.7M |
| Feb 26, 2026 | -- | -1.37 | -1.29 | $4.5M | $6.2M |
| Nov 6, 2025 | -- | -1.27 | -1.38 | $4.3M | $143000 |
| Aug 7, 2025 | -- | -1.13 | -1.23 | $394000 | $1M |
| May 8, 2025 | -- | -0.99 | -1.04 | $347910 | $361000 |
| Feb 27, 2025 | -- | -0.92 | -0.88 | $727270 | -- |
| Nov 12, 2024 | -- | -0.91 | -0.96 | $218091 | -- |
| Aug 8, 2024 | -- | -0.86 | -0.94 | $510000 | $399000 |
| May 9, 2024 | -- | -0.84 | -0.93 | $260000 | $640000 |
| Feb 28, 2024 | -- | -0.89 | -0.90 | $260000 | -- |
| Nov 7, 2023 | -- | -0.89 | -1.01 | $190000 | $346000 |
| Aug 8, 2023 | -- | -0.85 | -0.94 | $140000 | $988000 |
| May 4, 2023 | -- | -0.82 | -0.85 | $630000 | $2.7M |
| Feb 28, 2023 | -- | -0.82 | -0.84 | $250000 | $709000 |
Original Filings (SEC)
8-K2026-08-19 ↗
8-K2026-08-14 ↗
10-Q2026-08-03 ↗
8-K2026-08-03 ↗
8-K2026-07-10 ↗
8-K2026-07-06 ↗
8-K2026-06-22 ↗
10-Q2026-05-07 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
